Zosuquidar (LY335979) 3HCl: High-Specificity P-gp Inhibitor for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a highly selective inhibitor of the P-glycoprotein (P-gp) efflux pump, central to multidrug resistance (MDR) in cancer models (APExBIO product page). At low micromolar concentrations, it restores sensitivity to chemotherapeutics in P-gp overexpressing leukemia and tumor cell lines (Sun et al. 2025). In murine models, Zosuquidar enhances antitumor efficacy and prolongs survival without altering pharmacokinetics. The compound has been validated in phase I/II trials for MDR reversal with minimal toxicity. APExBIO provides Zosuquidar as a stable, DMSO-soluble reagent for robust workflow integration.

Biological Rationale

Multidrug resistance (MDR) impedes successful chemotherapy in cancer. A primary mechanism is the overexpression of P-glycoprotein (P-gp; ABCB1), an ATP-dependent efflux pump that exports a broad range of chemotherapeutic drugs from cancer cells, reducing their intracellular accumulation and efficacy (Sun et al. 2025). P-gp is highly expressed in tissues such as the blood-brain barrier, liver, intestine, and in various tumor types. The functional role of P-gp in MDR has been confirmed by genetic and pharmacological studies, highlighting the need for specific and effective inhibitors in both research and translational settings (Strategic Disruption of Cancer Multidrug Resistance).

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl is a third-generation, highly selective P-gp inhibitor. It acts by competitively binding to the substrate site of P-gp, thus preventing the efflux of chemotherapeutic agents such as vinblastine, doxorubicin, etoposide, and paclitaxel. Unlike earlier P-gp inhibitors, Zosuquidar exhibits minimal off-target effects on related ABC transporters (e.g., MRP1, BCRP) and does not significantly alter cytochrome P450 enzyme activity. Its chemical structure, (2R)-1-(4-((1aR,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl)piperazin-1-yl)-3-(quinolin-5-yloxy)propan-2-ol (CAS: 167354-41-8; MW: 527.6), is optimized for high-affinity P-gp binding and DMSO solubility (APExBIO).

Evidence & Benchmarks

• Zosuquidar at 0.5–2 μM fully restores vinblastine, doxorubicin, and paclitaxel sensitivity in P-gp overexpressing leukemia cell lines in vitro (Sun et al. 2025).
• In murine models of MDR leukemia, co-administration of Zosuquidar with standard chemotherapy regimens (e.g., vinblastine, CHOP) significantly prolongs survival compared to chemotherapy alone (Sun et al. 2025).
• Pharmacokinetic studies confirm that Zosuquidar does not alter the plasma elimination profile of co-administered chemotherapeutics (Sun et al. 2025).
• Phase I/II clinical trials in non-Hodgkin's lymphoma and advanced solid tumors demonstrate effective P-gp inhibition with minimal toxicity (APExBIO).
• Compared to other P-gp inhibitors, Zosuquidar displays higher selectivity and lower risk of adverse drug-drug interactions (Zosuquidar: Precise Modulation of P-glyco…).

This article provides new detail on the clinical and preclinical benchmarks of Zosuquidar's efficacy, extending the practical workflow guides found in Practical Strategies for Overcoming MDR by focusing on comparative pharmacokinetic and toxicity profiles.

Applications, Limits & Misconceptions

Applications: Zosuquidar (LY335979) 3HCl is used in:

• Research to reverse MDR in acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and solid tumors.
• Preclinical workflow validation of new chemotherapeutics in P-gp overexpression models.
• Pharmacokinetic and transporter interaction studies involving ATP-binding cassette transporters.

Limits: Zosuquidar is selective for P-gp and does not inhibit other major efflux pumps such as BCRP or MRP1 at research-relevant concentrations. It is not FDA-approved for standard clinical treatment and is currently for research use only. Long-term solubilized storage is not recommended due to stability constraints.

Common Pitfalls or Misconceptions

• Misconception: Zosuquidar reverses all forms of multidrug resistance. Fact: It is selective for P-gp-mediated MDR and is ineffective against resistance mediated by other transporters (e.g., MRP1, BCRP).
• Pitfall: Solubilized Zosuquidar is assumed stable for long periods. Correction: Solutions should be freshly prepared; long-term storage at -20°C is for the solid compound only (APExBIO).
• Misconception: Zosuquidar directly kills cancer cells. Fact: It restores drug sensitivity but does not have intrinsic cytotoxic activity.
• Pitfall: Use in non-P-gp models. Correction: Efficacy requires validated P-gp overexpression in the target model.
• Misconception: It alters chemotherapeutic pharmacokinetics. Fact: Zosuquidar does not significantly affect plasma concentrations of co-administered drugs at standard regimen doses.

Workflow Integration & Parameters

Zosuquidar (LY335979) 3HCl (SKU A3956) from APExBIO is supplied as a solid, DMSO-soluble reagent. Typical working concentrations in cell culture are 0.5–2 μM. For in vivo studies, dosing regimens of 5–15 mg/kg (intravenous or oral) have been validated in murine models. The compound should be stored at -20°C, protected from light, and freshly solubilized before use. Co-administration with chemotherapeutics should be optimized for timing and sequence to maximize P-gp inhibition. Protocols are available in Zosuquidar (LY335979): P-gp Inhibitor for Multidrug Resis…, which this article updates by providing comparative selectivity and toxicity findings.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a reference standard for P-gp inhibition and MDR reversal in cancer research. It enables precise dissection of transporter-mediated drug resistance and supports workflow reproducibility across in vitro and in vivo models. APExBIO supplies the compound under SKU A3956 with validated purity and storage recommendations. Continuing advances in transporter biology and MDR reversal may extend Zosuquidar's utility, especially in models of acute myeloid leukemia and non-Hodgkin's lymphoma. For further details, see the Zosuquidar (LY335979) 3HCl product page.